Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14662241 | 0.87 | AR (0.48) | ARALDH1A1SMN1; SMN2CYP19A1CYP11B1 | |
| SCHEMBL15832084 | 0.87 | AR (0.48) | ARALDH1A1SMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL14662597 | 0.85 | NPC1 (0.47) | ARALDH1A1SMN1; SMN2CYP19A1CYP11B1 | |
| SCHEMBL17460303 | 0.82 | AR (0.41) | ARCYP11B1CYP11B2IKBKETBK1 | |
| SCHEMBL17467724 | 0.82 | AR (0.49) | ARIKBKETBK1XDHTTR | |
| SCHEMBL29642279 | 0.81 | AR (0.55) | ARSCN9ASLC22A12 | |
| SCHEMBL875766 | 0.81 | AR (0.55) | ARSCN9ASLC22A12 | |
| SCHEMBL875806 | 0.81 | ALDH1A1 (0.68) | ARALDH1A1SMN1; SMN2CYP19A1TTR | |
| SCHEMBL5570382 | 0.80 | ALDH1A1 (0.53) | ARALDH1A1SMN1; SMN2CYP19A1SLC22A12 | |
| SCHEMBL876063 | 0.80 | PPARD (0.44) | ARTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10280146-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-05-07 | — | — | US | disclosed |
| US-20180009766-A1 | Pyrimidone Compounds Used as Lp-PLA2 Inhibitors and Pharmaceutical Compositions Thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-01-11 | — | — | US | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| WO-2016012916-A1 | 1,2,3,5-TETRAHYDROIMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES AND DISORDERS MEDIATED BY LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012916-A1 | 1,2,3,5-TETRAHYDROIMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES AND DISORDERS MEDIATED BY LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-01-28 | — | — | WO | disclosed |
| US-8975400-B2 | 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2015-03-10 | — | — | US | disclosed |
| US-8975400-B2 | 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2015-03-10 | — | — | US | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280146-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | PLA2G12B, PLA2G1B, PLA2G4A | AR 1513/4885ALDH1A1 579/4885SMN1; SMN2 2039/4885 |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | AR 3517/4885ALDH1A1 3675/4885SMN1; SMN2 4240/4885 |
| US-20180009766-A1 | Pyrimidone Compounds Used as Lp-PLA2 Inhibitors and Pharmaceutical Compositions Thereof | PLA2G12B, PLA2G1B, PLA2G4A | AR 1513/4885ALDH1A1 579/4885SMN1; SMN2 2039/4885 |
| US-20130030012-A1 | COMPOUNDS | LPCAT1, PLA2G7, PLAAT2 | AR 4420/4885ALDH1A1 2825/4885SMN1; SMN2 3417/4885 |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | AR 3517/4885ALDH1A1 3675/4885SMN1; SMN2 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.